Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains the only agent that provides durable complete responses. The optimal sequence of these agents remains uncertain. This retrospective multi-ins...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2014
Soggetti:
Clinical Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127096/
https://ncbi.nlm.nih.gov/pubmed/25075565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000044
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi